Premium
Synergistically Improved Anti‐tumor Efficacy by Co‐delivery Doxorubicin and Curcumin Polymeric Micelles
Author(s) -
Wang Jinling,
Ma Wenzhuan,
Tu Pengfei
Publication year - 2015
Publication title -
macromolecular bioscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 105
eISSN - 1616-5195
pISSN - 1616-5187
DOI - 10.1002/mabi.201500043
Subject(s) - curcumin , doxorubicin , chemistry , pharmacology , micelle , apoptosis , cytotoxicity , multiple drug resistance , drug delivery , efflux , chemotherapy , in vitro , medicine , biochemistry , aqueous solution , antibiotics , surgery , organic chemistry
P‐gp mediated drug efflux has been recognized as a major obstacle limiting the success of cancer chemotherapy. To overcome this issue, doxorubicin (DOX) and curcumin (Cur; P‐gp inhibitor and apoptosis inhibitor) co‐encapsulated pegylated polymeric micelles ((DOX+Cur)‐PMs) were designed, prepared and characterized to simultaneously deliver chemotherapeutic drug and multidrug resistance (MDR) modulator to tumor sites. The (DOX+Cur)‐PMs were spherical nano‐size particle, with a loading content of 6.83%, and high colloidal stability. Co‐delivery micelles exhibited excellent cytotoxicity by reversing MDR, promoting cellular uptake and enhancing cellular apoptosis in MCF7/Adr cells. The tumor growth inhibitory effect of (DOX+Cur)‐PMs in 4T1‐bearing mice was more effective compared with the combination solution of DOX and Cur and even DOX‐PMs. In conclusion, simultaneous delivery of DOX and Cur by (DOX+Cur)‐PMs has been demonstrated to be a promising approach for overcoming MDR and improving antitumor efficacy.